Alcohol and Alcoholism Vol. 35, No. 6, pp. 587-593, 2000
© 2000 Medical Council on Alcoholism
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NALTREXONE IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ABUSE
Department of Psychiatry, University of Edinburgh,
1 University Department of Medicine, Royal Free Campus, The Royal Free and University College Medical School, London,
2 St George's Hospital Medical School, London,
3 King's College Hospital Medical School, London, UK,
4 Dupont Pharmaceuticals Company, Wilmington, Delaware and
5 Medical University of South Carolina, Charleston, South Carolina, USA
Received 2 March 2000; first review notified 23 May 2000; accepted 25 May 2000
The opioid antagonist, naltrexone, is reported, in single centre studies, to improve the clinical outcome of individuals with alcohol dependence participating in outpatient psychosocial programmes. This is the first multicentre controlled study to evaluate the efficacy and safety of naltrexone as adjunctive treatment for alcohol dependence or abuse. Patients who met criteria for alcohol dependence (n = 169) or alcohol abuse (n = 6) were randomly assigned to receive double-blind oral naltrexone 50 mg daily (n = 90) or placebo (n = 85) for 12 weeks as an adjunct to psychosocial treatment. The primary efficacy variable was time to first episode of heavy drinking; secondary efficacy assessments included time to first drink, alcohol consumption, craving, and changes in the serum biological markers gamma-glutamyl transferase (GGT), and aspartate and alanine aminotransferases. Compliance was assessed by tablet counts and, in the naltrexone-treated group, by measurement of urinary concentrations of 6-ß-naltrexol. Forty-nine (58%) patients randomized to placebo and 53 (59%) randomized to naltrexone did not complete the study. In intention-to-treat analyses, there was no difference between groups on measures of drinking. The median reduction from baseline of serum GGT (P < 0.05) and the reductions in alcohol craving (Obsessive and Compulsive Drinking Scale: OCDS) were greater in the naltrexone group (P < 0.05), from approximately half-way through the study. Of 70 patients (35 placebo; 35 naltrexone) who met an a priori definition of compliance (80% tablet consumption, attendance at all follow-up appointments), those allocated to naltrexone reported consuming half the amount of alcohol (P < 0.05), had greater median reduction in serum GGT activity (P < 0.05), and greater reduction in alcohol craving (OCDS total score: P < 0.05; Obsessive subscale score: P < 0.05), compared to patients in the placebo group. Use of naltrexone raised no safety concerns. Naltrexone is effective in treating alcohol dependence/abuse in conjunction with psychosocial therapy, in patients who comply with treatment.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. L Olmsted and D. R Kockler Topiramate for Alcohol Dependence Ann. Pharmacother., October 1, 2008; 42(10): 1475 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Leontieva, J. A. Dimmock, P. W. Gately, L. Gallinger, R. Ploutz-Snyder, and S. L. Batki Voucher-Based Incentives for Naltrexone Treatment Attendance in Schizophrenia and Alcohol Use Disorders Psychiatr Serv, March 1, 2008; 59(3): 310 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rosner, S. Leucht, P. Lehert, and M. Soyka Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes J Psychopharmacol, January 1, 2008; 22(1): 11 - 23. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Laaksonen, A. Koski-Jannes, M. Salaspuro, H. Ahtinen, and H. Alho A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence Alcohol Alcohol., January 1, 2008; 43(1): 53 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Ray and K. E. Hutchison Effects of Naltrexone on Alcohol Sensitivity and Genetic Moderators of Medication Response: A Double-blind Placebo-Controlled Study Arch Gen Psychiatry, September 1, 2007; 64(9): 1069 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, X. Sun, and W. Sadee Different Effects of Opioid Antagonists on {micro}-, {delta}-, and {kappa}-Opioid Receptors with and without Agonist Pretreatment J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 544 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. SWIFT Emerging approaches to managing alcohol dependence Am. J. Health Syst. Pharm., March 1, 2007; 64(5_Supplement_3): S12 - S22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Peterson Improving adherence in patients with alcohol dependence: A new role for pharmacists Am. J. Health Syst. Pharm., March 1, 2007; 64(5_Supplement_3): S23 - S29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Luty What works in alcohol use disorders? Adv. Psychiatr. Treat., January 1, 2006; 12(1): 13 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K Killeen Long acting injectable naltrexone is effective and safe for treating alcohol dependence Evid. Based Ment. Health, November 1, 2005; 8(4): 100 - 100. [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. O'Brien Anticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications Am J Psychiatry, August 1, 2005; 162(8): 1423 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. RUBIO, G. PONCE, R. RODRIGUEZ-JIMENEZ, M. A. JIMENEZ-ARRIERO, J. HOENICKA, and T. PALOMO CLINICAL PREDICTORS OF RESPONSE TO NALTREXONE IN ALCOHOLIC PATIENTS: WHO BENEFITS MOST FROM TREATMENT WITH NALTREXONE? Alcohol Alcohol., May 1, 2005; 40(3): 227 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Garbutt, H. R. Kranzler, S. S. O'Malley, D. R. Gastfriend, H. M. Pettinati, B. L. Silverman, J. W. Loewy, E. W. Ehrich, and for the Vivitrex Study Group Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial JAMA, April 6, 2005; 293(13): 1617 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Lingford-Hughes, S. Welch, and D. J. Nutt Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, September 1, 2004; 18(3): 293 - 335. [PDF]
|
|
|
|
|
|
J. Chick, P. Lehert, and F. Landron Does Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence? J Psychopharmacol, December 1, 2003; 17(4): 397 - 402. [Abstract] [PDF]
|
|
|
|
 |
|
 S. S. O'Malley, B. J. Rounsaville, C. Farren, K. Namkoong, R. Wu, J. Robinson, and P. G. O'Connor Initial and Maintenance Naltrexone Treatment for Alcohol Dependence Using Primary Care vs Specialty Care: A Nested Sequence of 3 Randomized Trials Arch Intern Med, July 28, 2003; 163(14): 1695 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kiefer, H. Jahn, T. Tarnaske, H. Helwig, P. Briken, R. Holzbach, P. Kampf, R. Stracke, M. Baehr, D. Naber, et al. Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism: A Double-blind, Placebo-Controlled Study Arch Gen Psychiatry, January 1, 2003; 60(1): 92 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rubio, G. Ponce, J. Manzanares, J. D. Sinclair, H. Alho, M. Shinderman, J. H. Krystal, J. A. Cramer, and R. Rosenheck Naltrexone for Alcohol Dependence N. Engl. J. Med., April 25, 2002; 346(17): 1329 - 1331. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Krystal, J. A. Cramer, W. F. Krol, G. F. Kirk, R. A. Rosenheck, and the Veterans Affairs Naltrexone Cooperative Study Naltrexone in the Treatment of Alcohol Dependence N. Engl. J. Med., December 13, 2001; 345(24): 1734 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Fuller and E. Gordis Naltrexone Treatment for Alcohol Dependence N. Engl. J. Med., December 13, 2001; 345(24): 1770 - 1771. [Full Text] [PDF]
|
|
|
|
|
|
C. Streeton and G. Whelan NALTREXONE, A RELAPSE PREVENTION MAINTENANCE TREATMENT OF ALCOHOL DEPENDENCE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Alcohol Alcohol., November 1, 2001; 36(6): 544 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rubio, M. A. Jimenez-Arriero, G. Ponce, and T. Palomo NALTREXONE VERSUS ACAMPROSATE: ONE YEAR FOLLOW-UP OF ALCOHOL DEPENDENCE TREATMENT Alcohol Alcohol., September 1, 2001; 36(5): 419 - 425. [Abstract] [Full Text] [PDF]
|
|